Page 471 - ILAE_Lectures_2015

VNS offers different advantages and disadvantages to standard AEDs and its profile may
preferentially suit certain patients. Compliance is ensured and VNS does not typically
associate with central nervous system side effects. VNS is unlikely to render patients seizure
free and continued use of antiepileptic medication is usually necessary. The cost-benefit
analyses in severe epilepsy are particularly compelling and may lead to a more widespread
use in patients with frequent hospital admissions or who are on polypharmacy.

The increasing utilisation of responsive VNS and further development of transcutaneous
VNS offer exciting possibilities. These advances, coupled with deep brain stimulation in
epilepsy, mean that the role of neurostimulation in drug-refractory epilepsy is likely to
continue to expand.

References

1. SCHACHTER SC, WHELESS JW (2002) Vagus Nerve Stimulation 5 years after approval: a comprehensive
update. Neurology 59, S15-S29.

2. MORRIS GL 3rd, GLOSS D, BUCHHALTER J, MACK KJ, et al (2013) Evidence-based guideline update:
vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of
the American Academy of Neurology. Neurology 81(16):1453-9.

3. HENRY TR (2002) Therapeutic mechanisms of vagus nerve stimulation. Neurology 59 (Suppl 4), S3-14.
4. NEMEROFF, CB, MAYBERG, HS, KRAHL SE et al (2006) VNS Therapy in treatment-resistant depression:

clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 31, 1345-1355.
5. ALEXANDER GM, MCNAMARA JO (2012) Vagus nerve stimulation elevates seizure threshold in the

kindling model. Epilepsia 53(11), 2043-2052.
6. GRIMONPREZ A, RAEDT R, DAUWE I, MOLLET L et al (2015) Vagus nerve stimulation has antidepressant

effect in the kainic acid model for temporal lobe epilepsy Brain Stim 8(1) 13-20.
7. FRASCHINI M, PULIGHEDDU M, DEMURU M, POLIZZI L et al (2013) VNS induced desynchronization

in gamma bands correlates with positive clinical outcome in temporal lobe pharmacoresistant epilepsy.
Neurosci Lett 536, 14-8.
8. FRASCHNI M, DEMURU M, PULIGHEDDU M, FLORIDIA S et al. (2014) The re-organization of functional
brain networks in pharmaco-resistant epileptic patients who respond to VNS. Neurosci Lett 580, 153-157.
9. DE VOS CC, MELCHING L, VAN SCHOONHOVEN J et al (2011) Predicting success of vagus nerve
stimulation (VNS) from interictal EEG. Seizure 7, 541-545.
10. LOTVALL J, LUNDE H, AUGUSTINSON LE et al (1994) Airway effects of direct left-sided cervical vagal
stimulation in patients with complex partial seizures. Epilepsy Res 18(2), 149-154.
11. PRIVITERA MD, WELTY TE, FICKER DM, WELGE J (2002) Vagus nerve stimulation for partial seizures
(Cochrane Review). Cochrane Database Syst Rev 1, CD002896.
12. SCHACHTER SC (2003) Vagus nerve stimulation: efficacy, safety and tolerability in patients with epilepsy.
In: Vagus Nerve Stimulation, 2nd Edition, Schachter SC, Schmidt S (Eds). Martin Dunitz, London.
13. ELLIOTT R, MORSI A, KALHORN SP et al (2011) Vagus nerve stimulation in 436 consecutive patients with
treatment-resistant epilepsy: Long-term outcomes and predictors of response. Epilepsy Behav 20, 57-63.
14. Vagus Nerve Stimulation Study Group (1995) A randomized controlled trial of chronic vagus nerve stimulation
for treatment of medically intractable seizures. Neurology 45, 224-230.
15. Morris GL, Mueller WM (1999) Long-term treatment Vagus nerve stimulation in patients with refractory
epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 53(8), 1731-1735.
16. DEGIORGIO CM, SCHACHTER SC, HANDSFORTH A et al (2000) Prospective long-term study of vagus
nerve stimulation for the treatment of refractory seizures, Epilepsia 41(9), 1195-1200.
17. HANDFORTH A, DEGIORGIO CM, SCHACHTER SC et al (1998) Vagus nerve stimulation therapy for
partial-onset seizures: a randomized active-control trial. Neurology 51, 48-55.
18. MARSON AG, KADIR ZA, CHADWICK DW (1996) New antiepileptic drugs: a systematic review of their
efficacy and tolerability. Br Med J 313, 1169-1174.
19. MARSON AG, HUTTON JL, LEACH JP (2001) Levetiracetam, oxcarbazepine, remacemide and zonisamide
for drug resistant. localization-related epilepsy: a systematic review. Epilepsy Res 46(3), 259-270.
20. PANEBIANCO M, RIGBY A, WESTON J, MARSON AG (2015) Vagus nerve stimulation for partial seizures.
Cochrane Database Systematic Rev Apr 3, 4, CD002896.
21. CONNOR DE Jr, NIXON M, NANDA A, GUTHIKONDA B. (2012) Vagal nerve stimulation for the treatment
of medically refractory epilepsy: a review of the current literature. Neurosurg Focus 32(3):E1.
22. HOPPE C, WAGNER L, HOFFMANN JM, VON LEHE M, ELGER CE. (2013) Comprehensive long-term
outcome of best drug treatment with or without add-on vagus nerve stimulation for epilepsy: a retrospective
matched pairs case-control study. Seizure 22(2), 109-115.
23. KUBA R, BRÁZDIL M, KALINA M et al (2009) Vagus nerve stimulation: longitudinal follow-up of patients
treated for 5 years. Seizure 18(4), 269-274.
24. GHAEMI K, ELSHARKAWY AE, SCHULZ R et al (2010) Vagus nerve stimulation: outcome and predictors
of seizure freedom in long-term follow-up. Seizure 19(5), 264-268.